A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer.
| Autor: | Isakoff, S. J., Pulhalla, S., Shepherd, S. P., Falotico, N., Kaufman, B., Friedlander, M., Robson, M., Domchek, S., Garber, J., McKeegan, E., Chyla, B., Qian, J., Giranda, V. L. |
|---|---|
| Zdroj: | Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p114-115. 2p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|